Embla Medical hf. (OSSFF)
| Market Cap | 1.79B -8.9% |
| Revenue (ttm) | 958.30M +11.7% |
| Net Income | 85.63M +18.6% |
| EPS | 0.20 +19.1% |
| Shares Out | n/a |
| PE Ratio | 20.95 |
| Forward PE | 18.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Open | 4.150 |
| Previous Close | 4.300 |
| Day's Range | 4.150 - 4.150 |
| 52-Week Range | 4.150 - 5.325 |
| Beta | 0.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 21, 2026 |
About Embla Medical
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides os... [Read more]
Financial Performance
In 2025, Embla Medical's revenue was $928.69 million, an increase of 8.63% compared to the previous year's $854.89 million. Earnings were $83.34 million, an increase of 22.05%.
Financial StatementsNews
Embla Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 15% revenue growth (4% organic), stable margins despite tariffs and FX, and 21% bottom-line growth. Guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated, with segment strength in Prosthetics and neuro-orthotics and recovery expected in Patient Care.
Embla Medical Quarterly report: Q1 2026
Embla Medical has published its Q1 2026 quarterly earnings report on April 28, 2026.
Embla Medical Slides: Q1 2026
Embla Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Embla Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 15% reported sales growth and 21% net profit growth, with strong Prosthetics & Neuro Orthotics performance and margin pressure from FX and tariffs. Full-year guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated.
Embla Medical Quarterly report: Q1 2026
Embla Medical has published its Q1 2026 quarterly earnings report on April 28, 2026.
Embla Medical Slides: Q1 2026
Embla Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Embla Medical Slides: Investor presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Embla Medical Transcript: Life Science-dagen 2026
A global leader in mobility solutions is driving growth through innovation, acquisitions, and expanding access to advanced prosthetics and neuro-orthotics. Key growth comes from functional trade-up, recurring sales, and new market penetration, while challenges include reimbursement, tariffs, and geopolitical risks.
Embla Medical Slides: FY 2026
Embla Medical has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 4, 2026.
Embla Medical Earnings Call Transcript: Q4 2025
Solid organic and acquisition-driven growth was achieved, with strong cash flow and resilient margins despite tariffs and FX headwinds. Guidance for 2026 anticipates 5%-8% organic growth and 20%-22% EBITDA margin, supported by efficiency gains and new product launches.
Embla Medical Annual report: Q4 2025
Embla Medical has published its Q4 2025 annual report on February 3, 2026.
Embla Medical Quarterly report: Q4 2025
Embla Medical has published its Q4 2025 quarterly earnings report on February 3, 2026.
Embla Medical Slides: Q4 2025
Embla Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Embla Medical Earnings Call Transcript: Q4 2025
Solid organic sales growth and profitability were achieved in 2025, driven by strong performance in prosthetics and neuroorthotics, with robust cash flow and margin resilience despite FX and tariff headwinds. 2026 guidance targets 5%-8% organic growth and 20%-22% EBITDA margin.
Embla Medical Annual report: Q4 2025
Embla Medical has published its Q4 2025 annual report on February 3, 2026.
Embla Medical Quarterly report: Q4 2025
Embla Medical has published its Q4 2025 quarterly earnings report on February 3, 2026.
Embla Medical Slides: Q4 2025
Embla Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Embla Medical Slides: Investor presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on February 3, 2026.
Embla Medical hf: Interim Report Q4 and Full Year 2025
COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full Year 2025 Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the fourth qua...
Embla Medical Slides: SEB Nordic Seminar presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on January 9, 2026.
Embla Medical Earnings Call Transcript: Q3 2025
Q3 2025 saw 7% organic and 11% reported sales growth, led by double-digit gains in prosthetics and neuroorthotics, while patient care and bracing/supports lagged. EBITDA margin held at 22%, and full-year guidance for 5%-6% organic growth and 20%-21% EBITDA margin was reiterated.
Embla Medical Quarterly report: Q3 2025
Embla Medical has published its Q3 2025 quarterly earnings report on October 21, 2025.
Embla Medical Slides: Q3 2025
Embla Medical has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 21, 2025.
Embla Medical Earnings Call Transcript: Q3 2025
Q3 2025 saw 7% organic sales growth, led by double-digit gains in prosthetics and new orthotics, with EBITDA margin at 22%. Guidance for 5%-6% organic growth and 20%-21% EBITDA margin is reiterated, while tariffs and internal changes impact patient care and bracing segments.
Embla Medical Quarterly report: Q3 2025
Embla Medical has published its Q3 2025 quarterly earnings report on October 21, 2025.